KOSPIBiotech & Pharma214390

Kyongbo Pharmaceutical

₩4,930▲ 0.20%2026-11-18 close
Market Cap
₩117.9B
Turnover
₩23,864,750
Volume
4.9K
Shares out.
23.9M
PER
101.8×
PBR
0.8×
EPS
₩48
Dividend Yield
1.02%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Kyongbo: ADC Build-Out Ahead of an Earnings Recovery Test

Kyongbo is growing revenue in its API core while building an ADC CDMO plant, but profitability had weakened through the third quarter of 2026, and whether the plant turns into earnings is the next test.

  1. 1

    Revenue for 2025 was KRW 264.1 billion, up 10.7% year on year, while operating profit was KRW 3.52 billion, down 66.3%.

  2. 2

    Operating profit for the third quarter of 2026 was KRW 99.68 million, down 79.0% year on year, and the net loss attributable to controlling shareholders was KRW 867 million, a swing into loss.

  3. 3

    Cumulative revenue for January to September 2026 was KRW 207.5 billion on a provisional basis, up 7.6%, and cumulative operating profit was KRW 1.74 billion, down 42.0% (provisional disclosure dated October 30, 2026).

  4. 4

    The Asan ADC plant is planned with KRW 96 billion of investment from August 2024 to December 2026, and the company has set out a roadmap for clinical-supply production from 2027 after completion in the fourth quarter of 2026.

  5. 5

    A raw-material supply contract with a Chinese counterparty was terminated on the counterparty's notice in April 2026, and the largest shareholder group holds 60.56% of the shares.

02

Business structure

Kyongbo Pharmaceutical was founded in 1987 as a raw-material drug specialist, expanded into finished drugs in 2002, and listed on the KOSPI market in 2015. The business has two divisions, active pharmaceutical ingredients (APIs) and finished drugs.

The API division produces and sells general APIs, cephalosporin antibiotic APIs, and anticancer and highly potent APIs, with competitiveness built mainly in cephalosporin and anticancer APIs.

The finished-drug division sells prescription and over-the-counter products, including circulatory drugs, antibiotics and inhalation anesthetics. Finished-drug revenue reached KRW 126.5 billion in 2025, growing more than 30.7% year on year and lifting overall revenue.

Exports go to about 16 countries, supported by certifications from regulators including the US FDA and the European EDQM.

In the first half of 2026, raw-material exports rose as Japanese use of generics increased, and demand for the non-opioid analgesic injection grew with wider ERAS programs and tighter prescribing limits on opioid analgesics.

The company has named ADC CDMO as its next growth engine and is developing payload-linker and conjugation technology in-house. The largest shareholder group holds 60.56% of the shares, and the free float ratio is 38.20%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩67B₩500M0.7%
2025Q4₩71.2B₩500M0.7%
2026Q1₩66.1B₩700M1.1%
2026Q2₩75.2B₩900M1.2%
2026Q3₩66.2B₩99,681,7900.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩196.3B₩1.4B₩600M0.7%0.4%67.4%
2023₩216.4B₩5.5B₩3B2.6%2.1%84.4%
2024₩238.6B₩10.5B₩4.6B4.4%3.2%94.2%
2025₩264.1B₩3.5B₩200M1.3%0.1%119.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue was KRW 196.3 billion in 2022, KRW 216.4 billion in 2023, KRW 238.6 billion in 2024 and KRW 264.1 billion in 2025, rising three years in a row from 2023 through 2025, with 2025 the largest year of 2022 to 2025.

Operating profit over the same period went from KRW 1.39 billion in 2022 to KRW 5.54 billion in 2023, up 298.1%, and KRW 10.5 billion in 2024, up 88.5%, before falling to KRW 3.52 billion in 2025, down 66.3%. The operating margin moved from 0.7% in 2022 and 2.6% in 2023 to 4.4% in 2024, then fell to 1.3% in 2025.

In 2025, selling and administrative expenses rose 20.9%, from KRW 66.7 billion to KRW 80.6 billion, and ordinary R&D expenses rose 49.2%, from KRW 12.2 billion to KRW 18.2 billion, lifting the R&D share of revenue from 5.1% to 6.9%.

Higher commission fees and ADC R&D spending were cited as the factors that weighed on profitability. Net profit attributable to controlling shareholders was KRW 4.64 billion in 2024 and fell 96.1% to KRW 182 million in 2025, and net profit including non-controlling interests was KRW 182 million in 2025.

Operating cash flow was KRW 10.1 billion in 2022, KRW 4.84 billion in 2023, KRW 149 million in 2024 and KRW 7.46 billion in 2025, recovering from the 2024 low.

Quarterly operating profit was KRW 474 million in the third quarter of 2025, KRW 516 million in the fourth quarter, KRW 713 million in the first quarter of 2026 and KRW 930 million in the second quarter, then fell to KRW 99.68 million in the third quarter of 2026.

Second-quarter 2026 revenue of KRW 75.2 billion rose 13.8% from the prior quarter, while third-quarter revenue of KRW 66.2 billion fell 12.1%.

Net profit attributable to controlling shareholders moved from KRW 3.03 billion in the third quarter of 2025 to a net loss of KRW 433 million in the fourth quarter, a net loss of KRW 530 million in the first quarter of 2026, a profit of KRW 2.97 billion in the second quarter, and a net loss of KRW 867 million in the third quarter, with the last four quarters totaling KRW 1.14 billion.

05

Industry analysis

ADC is a next-generation anticancer modality that attaches cytotoxic drugs to antibodies, the global market is growing quickly, and manufacturing difficulty is driving demand for specialist CDMO services.

Analysts say ADC CDMO has higher entry barriers than general biologics CMO work, so a successful foothold could become a high-value business.

Samsung Biologics and Alteogen are among the listed companies in the same biopharma sector, and Kyongbo is taking a different route, starting from raw-material manufacturing and moving toward CDMO.

Kyongbo is seen as able to connect its chemical synthesis, experience with highly potent APIs and sterile injectable manufacturing to the core technologies needed for ADC production. The Korea IR Council has noted that the industry is watching whether Kyongbo can move beyond a simple raw-material supplier.

The API market is extending into complex synthesis, customer-specific manufacturing and materials for CDMO and next-generation modalities.

For broader pharma profitability pressure in the third quarter, analysts pointed to a mix of R&D and market-expansion spending, the base effect of technology-fee income, weakness in core businesses and accounting for expected costs.

Kyongbo's third-quarter 2026 operating decline should be read against both these sector factors and its own investment costs, and company-specific causes should be confirmed in periodic filings.

06

Outlook

In its voluntary 2026 corporate value-up disclosure, the company set out completion of the ADC plant, wider AI-based workflows and a global ESG regulatory compliance project as its core goals.

Detailed tasks include equipment qualification, introduction of an AI platform, building an ESG platform, managing labor costs and improving margins through organizational streamlining, and expanding investor relations.

The Asan site has been building a dedicated ADC GMP facility since August 2024, with a plan to invest KRW 96 billion in total through December 2026.

The company has also outlined an integrated CDMO system centered on its Yongin research center and the Asan GMP plant, covering preclinical, clinical and commercial production. Its roadmap calls for completion in the fourth quarter of 2026 and clinical-supply production from 2027.

In a late-March 2026 report, the Korea IR Council projected 2026 revenue of KRW 282.5 billion and operating profit of KRW 8.8 billion, but cumulative operating profit for January to September 2026 was KRW 1.74 billion on a provisional basis, a wide gap from that projection.

Fourth-quarter 2026 results have not yet been disclosed and will first appear as full-year figures in the 2026 annual report.

Some analysts say valuation could be re-rated if ADC CDMO results become visible, while others warn that delays in customer development schedules or commercialization failures could push back CDMO demand.

07

Valuation

PER
101.8×
PBR
0.8×
ROE
0.8%
EPS
₩48
BPS
₩6,425
Dividend per share
₩50

The current multiples need to be read alongside the earnings trend. Net profit attributable to controlling shareholders over the last four quarters totals only KRW 1.14 billion, so earnings-based multiples are heavily affected by the low-earnings period.

Analysts in early 2026 described the price-to-book ratio as conservative relative to industry peers, and interpreted the apparently high price-to-earnings ratio as a distortion from earnings recovering from a low base after weak 2025 results.

The Korea IR Council judged that the share price is formed mainly around the stability of the API core business and its existing asset value, and that the valuation ceiling could open as ADC CDMO results are confirmed. The council did not present an investment opinion or a target price.

Dividend capacity also depends on controlling-shareholder net profit, which swung from KRW 182 million in 2025 to a net loss of KRW 867 million in the third quarter of 2026, so dividend metrics should be read with the earnings trend. Analyst views differ on how much of the ADC business outcome the share price currently reflects.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Foundation for ADC CDMO entry

The company is seen as able to connect its highly potent chemical synthesis and sterile injectable manufacturing experience to the core technologies needed for ADC production.

KRW 96 billion is being invested at the Asan plant from August 2024 to December 2026, with a roadmap to start clinical-supply production from 2027 after completion. Together with the Yongin research center, the company plans a system covering preclinical through commercial production.

Revenue growth and product mix

Revenue for 2025 was KRW 264.1 billion, up 10.7%, and finished-drug revenue reached KRW 126.5 billion, growing more than 30.7%. Cumulative revenue for January to September 2026 was KRW 207.5 billion on a provisional basis, up 7.6% year on year. Press coverage said second-quarter 2026 revenue of KRW 75.2 billion was the highest of the last three years.

Export base and demand trends

Regulatory certifications from the US FDA and the European EDQM support exports to about 16 countries. In the first half of 2026, raw-material exports rose on wider generic use in Japan, and demand for non-opioid analgesics grew with wider ERAS programs and tighter opioid prescribing limits. Some analysts also noted that the profit contribution from raw-material exports is limited by costs.

09

Bear factors

Falling core profitability

The operating margin rose from 0.7% in 2022 to 4.4% in 2024 and then fell to 1.3% in 2025. Third-quarter 2026 operating profit of KRW 99.68 million was down 79.0% year on year, and a net loss of KRW 867 million attributable to controlling shareholders marked a swing into loss.

Net profit attributable to controlling shareholders over the last four quarters totals KRW 1.14 billion, a thin earnings base relative to revenue.

Cost structure and R&D burden

Selling and administrative expenses rose 20.9% in 2025, from KRW 66.7 billion to KRW 80.6 billion, and ordinary R&D expenses rose 49.2%, from KRW 12.2 billion to KRW 18.2 billion. Press reports put the R&D share of revenue at 10.1% in the first quarter of 2026. Higher commission fees and ADC R&D spending were named as factors that weighed on 2025 profitability.

Financial strain and investment cash outflow

The debt-to-equity ratio rose from 67.4% in 2022 to 119.3% in 2025, and total liabilities at the end of 2025 of KRW 173.8 billion exceeded total equity of KRW 145.7 billion.

Investing cash flow in 2025 was negative KRW 38.0 billion, larger than the negative KRW 14.6 billion of the prior year, with KRW 41.5 billion spent on property, plant and equipment. Operating cash flow recovered to KRW 7.46 billion in 2025 after only KRW 149 million in 2024.

10

Risk factors

Clinical and customer dependence

Many ADC pipelines are still in clinical stages, so if customers' development schedules slip or commercialization fails, CDMO demand could arrive later than expected. Analysts flagged depreciation burdens, higher fixed costs and delayed monetization from low utilization in the early stage of the plant investment. The investment only shows up in earnings once plant utilization rises.

Counterparty and China exposure

A disclosure dated April 10, 2026 reported that a raw-material supply contract with Guangdong Landu Pharmaceutical was terminated on the counterparty's notice. The contract had been set to run through December 31, 2027, and the termination amount was disclosed as KRW 88.7 million.

The company described the notice as unilateral, citing changes in China's drug-market policy and falling prices. Policy shifts affecting specific counterparties or countries remain a risk to raw-material revenue.

Governance and succession

The largest shareholder group holds 60.56% of the shares, and the free float ratio is 38.20%. Some press reports pointed to the stakes held by the children of the controlling family, suggesting the holding could serve as a lever for group succession.

The same coverage said that if ADC returns are delayed and weak profitability persists, the succession plan could be disrupted.

11

What to watch next

  1. December 2026

    Check whether the Asan ADC GMP facility is completed and the KRW 96 billion investment plan is closed out. Utilization and customer wins after completion are the starting point for CDMO monetization.

  2. Late March 2027

    The 2026 annual report will show full-year 2026 operating profit and operating margin, and it is the first periodic filing to include fourth-quarter 2026 results within the annual totals.

  3. Around late April 2027

    Watch the provisional first-quarter 2027 results. The timing is based on the precedent of the first-quarter 2026 provisional disclosure, released on April 29, 2026.

  4. During 2027

    Check whether clinical-supply production starts as planned and how many customers are secured. Whether the roadmap is met is the point at which ADC CDMO performance can be gauged.

12

Overall view

Kyongbo is an API company that exports raw-material drugs for cephalosporin antibiotics and anticancer uses to about 16 countries, and its 2025 revenue of KRW 264.1 billion marked a third straight annual increase.

Over the same period, operating profit fell to KRW 3.52 billion and the operating margin dropped to 1.3%, and the third quarter of 2026 brought operating profit of KRW 99.68 million and a net loss of KRW 867 million attributable to controlling shareholders.

The company plans to complete its KRW 96 billion Asan ADC CDMO plant in December 2026, so plant costs are landing before monetization. Strengths are revenue growth and an expanding capability toward higher-value CDMO work.

Weaknesses are rising selling and R&D costs, a debt-to-equity ratio that climbed to 119.3%, and revenue volatility from the April 2026 supply-contract termination. Analysts broadly agree that the outcome depends on whether ADC results become visible.

The next checkpoints are completion of the Asan plant in December 2026, the full-year operating margin in the 2026 annual report, and the provisional first-quarter 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. m.news.nate.com
  3. huffingtonpost.kr
  4. dailypharm.com
  5. dailyinvest.kr
  6. press9.kr
  7. m.thinkpool.com
  8. m.news.nate.com
  9. medifonews.com
  10. m.saramin.co.kr
  11. vegannews.co.kr
  12. edaily.co.kr
  13. medipana.com
  14. hitnews.co.kr
  15. kr.investing.com
  16. kr.investing.com
  17. medifonews.com
  18. medipana.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis